Zethraeus N, Ström O, Borgström F, Kanis J A, Jönsson B
Centre for Health Economics, Stockholm School of Economics, P.O. Box 6501, S-113 83 Stockholm, Sweden.
Osteoporos Int. 2008 Jun;19(6):819-27. doi: 10.1007/s00198-007-0511-0.
This paper assessed the cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden, using one model and a societal perspective. Cost-effective scenarios were found in all these chronic disorders. These findings are of relevance for decisions on the efficient allocation of health care resources.
There is a need to assess the cost-effectiveness (CE) of treatment of osteoporosis from a societal perspective and to relate this to the CE of interventions in other disease areas. This is of relevance for decisions on the efficient allocation of health care resources within and between disease areas. The purpose of the paper was to estimate the CE of the treatment and prevention of osteoporosis and to put that into the perspective of treating hypertension and hyperlipidaemia. The CE was assessed for different high risk female populations aged 50-80 years.
The estimation of CE was based on a model populated with data for Sweden.
Compared to no intervention, a 5-year treatment of osteoporosis, hypertension, and hyperlipidaemia, is cost effective for most of the assessed high risk female populations. The cost per gained quality adjusted life year (QALY) for the treatment of a 70-year-old woman never exceeded SEK 330,000 (US$ 44,000), which is generally judged as an acceptable cost for a gained QALY.
The study demonstrates that it is possible to produce reliable estimates of the CE of treatments in different disease areas within the context of a single model.
本文采用单一模型并从社会角度评估了瑞典高危骨质疏松、高血压和高脂血症女性的治疗成本效益。在所有这些慢性疾病中都发现了具有成本效益的方案。这些发现对于有效分配卫生保健资源的决策具有重要意义。
有必要从社会角度评估骨质疏松症治疗的成本效益，并将其与其他疾病领域干预措施的成本效益相关联。这对于疾病领域内和疾病领域之间有效分配卫生保健资源的决策具有重要意义。本文的目的是估计骨质疏松症治疗和预防的成本效益，并将其置于治疗高血压和高脂血症的背景下进行考量。对50至80岁不同高危女性人群的成本效益进行了评估。
成本效益的估计基于一个用瑞典数据填充的模型。
与不进行干预相比，对大多数评估的高危女性人群而言，对骨质疏松症、高血压和高脂血症进行5年治疗具有成本效益。治疗一名70岁女性每获得一个质量调整生命年（QALY）的成本从未超过330,000瑞典克朗（44,000美元），这通常被认为是获得一个QALY可接受的成本。
该研究表明，在单一模型的背景下，可以对不同疾病领域治疗的成本效益进行可靠估计。
